http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Belden launches ProLinx Edge gateway for industrial networks
-
Bitdeer breaks ground on $36M Nevada manufacturing facility
-
EMA clears commercially made GP2 for use in Greenwich LifeSciences trial
-
Rubrik plans £375M UK investment, names London EMEA HQ
-
Ionis drug eplontersen misses primary endpoint in heart trial
-
Quest Diagnostics integrates cancer tests into Flatiron's OncoEMR platform
-
AIAI Holdings unit launches Gate AI security layer for AI apps
-
Beazer rejects Dream Finders' $32 offer, cites missing standstill pact
-
UroGen gets FDA IND clearance for bladder cancer virus therapy
-
Hestia Insight and Escher AI partner on capital markets AI tools
-
Abitibi Metals names new CFO, halts drilling on Quebec fire order
-
DeFi Technologies shareholders elect directors, approve share consolidation
-
Vishay launches four 40 V MOSFETs for motor control circuits
-
AMTD expands branded hotel network across five countries
-
Praxis strikes deal with Remagine Labs on transdermal ET drug patch
-
Tvardi Therapeutics reports Phase 1 data for TTI-109 STAT3 inhibitor
-
Walmart and Sam's Club cut prices on summer groceries and essentials
-
Context Therapeutics added to Russell 2000 and Russell 3000 indexes
-
Blackstone to acquire Dresser Utility Solutions from First Reserve
-
HII adds Halimar Shipyard to its Romulus USV production network
-
TG Therapeutics starts Phase 2 trial of Briumvi for schizophrenia
-
VERAXA Biotech targets first BiTAC candidate IND-ready by 2028
-
Ionis completes enrollment in Phase 3 Angelman syndrome study
-
American Lithium names Amandip Singh to its board of directors
-
Hilton Grand Vacations names Carnival Cruise Line president to board
-
Vishay launches multi-turn position sensor at 40% lower cost
-
Kraken Robotics closes $615M Covelya acquisition, raises 2026 outlook
-
Veraxa Biotech starts cell line development with ATUM for cancer therapy
-
PBCN drops legal challenge, backs Denison Mines uranium project
-
Securitize goes public on NYSE after SPAC merger closes
-
HII starts construction on destroyer John F. Lehman (DDG 137)
-
Interactive Brokers reports June trading metrics with 53% DART rise
-
Belden completes acquisition of Ruckus Networks from Vistance
-
MediGuide launches digital platform connecting insurers and health partners
-
Check Point cloud firewall now available on AWS European Sovereign Cloud
-
Blackline Safety goes private after Francisco Partners acquisition
-
Vishay launches six SMD polymer PTC thermistor series
-
Interactive Brokers adds Nextrade ATS for Korean equity trading
-
Klim and Research Frontiers strike smart glass licensing deal
-
NurExone closes private placement raising C$627,795
-
Schneider Electric extends EcoCare service plan to 3-phase UPS
-
Cogent Biosciences files NDA for bezuclastinib in advanced mastocytosis
-
Palvella Therapeutics adds Matt Pauls to its board of directors
-
Novocure's Optune Pax wins CE Mark for pancreatic cancer
-
FDA extends review of Praxis drug for rare epilepsy to December 2026
-
Norwegian Cruise Line names Lee Applbaum as chief marketing officer
-
AbbVie's epcoritamab combo meets primary endpoint in lymphoma trial
-
Digital Realty to buy Blackstone's stake in 3 Virginia data centers
-
Palvella files first NDA module for rare lymphatic malformation drug
-
Merck reaches deal to expand HIV drug access via ADAP programs

